- eXmoor Pharma and Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS) have announced a strategic partnership to provide an integrated service for cell and gene therapy developers.
- The collaboration combines donor material sourcing, apheresis collection, process development, and GMP manufacturing to deliver an end-to-end pathway from donor to patient.
eXmoor Pharma, a UK-based integrated cell and gene therapy CDMO, has entered a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS). The collaboration brings together two organisations with complementary capabilities to support developers of both autologous and allogeneic cell therapies.
The agreement will see Anthony Nolan’s CT&LS provide starting material through its donor register of more than 900,000 HLA-typed donors, a cord blood programme, bioinformatics expertise, and its newly opened apheresis collection centre in Nottingham. With over 50 years of experience in donor care, the organisation will supply ethically sourced material for clinical development.
eXmoor will process the collected material at its Bristol GMP facility, which offers integrated process development, fill-finish, and manufacturing services. The CDMO has passed Anthony Nolan CT&LS’s ethical review board, ensuring aligned standards of donor and patient care across the collaboration.
Lucy Foley, CEO of eXmoor Pharma, said: “Together, we can offer cell therapy developers a truly integrated path from donor to patient. This partnership reinforces our commitment not only to technical excellence but also to ethical responsibility, keeping both donors and patients at the centre of everything we do.”
By working closely from the earliest stages, the two organisations aim to streamline development timelines, reduce complexity, and provide a fully joined-up, ethically driven solution for the delivery of advanced therapies.
